lipodystrophy is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
There are many reasons why an excited state can be metastable. The most common mechanism is by suppression of gamma decay of excited nuclei, making the decay route a forbidden transition. Spin is conserved, and a photon has spin 1 ħ. Thus, if a decay route would require a change of ≥ 2 ħ (any possible change is always integer) in angular momentum, then the gamma decay would become highly suppressed. For example, if the decay requires the nucleus to change spin by 2 ħ, then it must emit 2 photons at once. This is a 3-body interaction, which is much weaker than a 2-body interaction, and thus occurs at a much lower rate. In general, each additional unit of spin larger than 1 that the emitted gamma ray must carry inhibits decay rate by about 5 orders of magnitude. As the excited energy state lowers, eventually internal conversion (IC) and internal pair production (IP) takes over. The decay of 180mTa from spin-9 state to spin-2 state changes spin by 7 ħ. This suppresses the rate of gamma emission so much that the decay rate is essentially equal to the rate of IC, in agreement with the above. When the nucleus begins and ends with 0 spin, it cannot decay via single photo gamma emission. The only possible routes are IC, internal pair production, or two-photon gamma emission. Usually IC and IP dominates over two-photon gamma emission.
=== Cardiovascular === Adropin also appears to have cardiovascular effects. It has been implicated in the regulation of endothelial function, which is essential for maintaining blood vessel health. Dysfunction in endothelial cells can contribute to conditions such as atherosclerosis and hypertension. Some studies suggest that adropin may have a protective role in cardiovascular health by promoting the dilation of blood vessels and reducing oxidative stress. In mice, adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. In rats, adropin treatment alleviated diabetes related myocardial fibrosis and diastolic dysfunction, and enhanced the therapeutic potential of mesenchymal stem cells in myocardial infarction.
=== Defunct === Liaison Committee for a Revolutionary Workers International, founded by former militants of the Argentinian MAS and PO Committee for a Workers' International (CWI), 1974–2019 – split into Committee for a Workers' International (Refounded) and International Socialist Alternative Coordinating Committee for the Refoundation of the Fourth International, CCRCI (2004-2020) International League for the Reconstruction of the Fourth International (ILRFI), 1976–1995 Workers International to Rebuild the Fourth International (WIRFI) International Revolutionary Marxist Tendency (TMRI), 1965–1992 Permanent Revolution Revolutionary Workers Ferment (Fomento Obrero Revolucionario, FOR) Trotskyist International Liaison Committee, 1979–1984 Tendencia Cuartainternacionalista Fourth International (ICR), also called FI (La Verité) or FI (International Secretariat) 1981–2015 Socialist Network (Post-Trotskyist, split from IMT) International Trotskyist Opposition] (ITO) 2022–2025 (Dissolved into LIS-ISL) League for the Fifth International (L5I), founded by expelled members of the IST. (1989-2025)
Sources: en.wikipedia.org
It controls food intake and energy expenditure by acting on receptors in the mediobasal hypothalamus. Leptin binds to neuropeptide Y (NPY) neurons in the arcuate nucleus in such a way as to decrease the activity of these neurons. Leptin signals to the hypothalamus which produces a feeling of satiety. Moreover, leptin signals may make it easier for people to resist the temptation of foods high in calories. Leptin receptor activation inhibits neuropeptide Y and agouti-related peptide (AgRP), and activates α-melanocyte-stimulating hormone (α-MSH). The NPY neurons are a key element in the regulation of hunger; small doses of NPY injected into the brains of experimental animals stimulates feeding, while selective destruction of the NPY neurons in mice causes them to become anorexic. Conversely, α-MSH is an important mediator of satiety, and differences in the gene for the α-MSH receptor are linked to obesity in humans. Leptin interacts with six types of receptors (Ob-Ra–Ob-Rf, or LepRa-LepRf), which in turn are encoded by a single gene, LEPR. Ob-Rb is the only receptor isoform that can signal intracellularly via the JAK-STAT and MAPK signal transduction pathways, and is present in hypothalamic nuclei. Once leptin has bound to the Ob-Rb receptor, it activates the stat3, which is phosphorylated and travels to the nucleus to effect changes in gene expression, one of the main effects being the down-regulation of the expression of endocannabinoids, responsible for increasing hunger.
=== Bandwidth === DisplayPort 1.2 has more bandwidth at 21.6 Gbit/s (17.28 Gbit/s plus overhead) as opposed to HDMI 2.0's 18 Gbit/s (14.4 Gbit/s plus overhead). DisplayPort 1.3 increased the bandwidth to 32.4 Gbit/s (25.92 Gbit/s plus overhead). HDMI 2.1 matched that by increasing the bandwidth up to 48 Gbit/s (42.67 Gbit/s plus overhead), adding an additional TMDS link in place of clock lane. In 2019, DisplayPort 2.0 once again achieved the bandwidth superiority of 80.0 Gbit/s. DisplayPort can also share bandwidth through the use of the Multi-Stream Transport (MST), which enables a single DP port to carry signals of several devices, to be demultiplexed at a branch hub.
Additionally, recombinant subunit vaccines are popular candidates for the development of vaccines against infectious diseases (e.g. tuberculosis, dengue). Recombinant subunit vaccines are considered to be safe for injection. The chances of adverse effects vary depending on the specific type of vaccine being administered. Minor side effects include injection site pain, fever, and fatigue, and serious adverse effects consist of anaphylaxis and potentially fatal allergic reaction. The contraindications are also vaccine-specific; they are generally not recommended for people with the previous history of anaphylaxis to any component of the vaccines. Advice from medical professionals should be sought before receiving any vaccination.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.